Monitorização terapêutica da olanzapina em pacientes esquizofrênicos / Therapeutic monitoring of olanzapina in schizophrenic patients

AUTOR(ES)

Marina Salviato Balbão Santiago Fonseca

DATA DE PUBLICAÇÃO

2009

RESUMO

The olanzapine is an atypical antipsychotic drug used to treat schizophrenia. How adverse effects related to its use, are obesity, hyperlipidemia, diabetes mellitus type II and hypertension, may result in the development of metabolic syndrome. This study aims to carry out monitoring therapy in patients in treatment with olanzapine, establishing a possible correlation between the dose-plasma concentration and potentiation of the risk to adverse reactions, providing clinical support in the effectiveness of treatment. Analysis of anthropometric parameters (weight, body mass index, arm circumference, circumference of the abdomen, the hip circumference, triceps skinfold thickness, biciptal skin fold, subscapular skin fold, skin fold suprailíaca, strength, percentage of fat mass and metabolic rate basal), hemodynamic parameters (systolic blood pressure, diastolic blood pressure and heart rate) and biochemical parameters (aspartate aminotranferase, alanine aminotransferase, gamma glutamyl transferase, creatinine, uric acid, amylase, insulin, total bilirubin, glucose, calcium, sodium and potassium ), lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides), concentration of homocysteine and C-reactive protein, are relevant in so far represent important markers of changes related to metabolic disorders and atherosclerotic risk. As obesity and coronary diseases can induce such changes, which is important to evaluate the risk that the weight gain induced by olanzapine brings to the schizophrenic patient. Statistical analysis was performed using a mixed effect linear model, suitable for analysis of measurements taken over a pre-established. The significance level was set at p <0.05.

ASSUNTO(S)

homocisteína homocysteine monitorização terapêutica olanzapine therapeutic monitoring olanzapina

Documentos Relacionados

• Avaliação de dados antropométricos, hemodinâmicos e metabólitos em pacientes esquizofrênicos que utilizam a olanzapina
• Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics
• Determination of gene expression and proteome of brain tissue from schizophrenic patients
• Experiências de vida de pacientes esquizofrênicos e seus familiares: uma perspectiva cultural da doença.
• Avaliação técnica SPME/LC na análise de antidepressivos em amostra de plasma para fins de monitorização terapêutica